Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ouro Medicines

Request full access

Biotechnology firm advancing immune reset therapeutics for chronic immune-mediated diseases with a robust clinical pipeline

South San Francisco, United StatesFounded 2024Biotech & Life Sciences

About Ouro Medicines

Ouro Medicines is a biotechnology company focused on developing immune reset therapeutics aimed at treating chronic immune-mediated diseases. The company operates in the biopharmaceutical sector, targeting patients who suffer from conditions that involve the immune system. Ouro Medicines leverages its scientific expertise and a strong track record in advancing cell-depleting therapies through clinical stages. The business model revolves around research and development, with a significant portion of its funding directed towards creating novel T cell engagers that have the potential to reset the immune system. Ouro Medicines generates revenue through partnerships and collaborations, as well as through the development and commercialization of its therapeutic assets. The company was founded by Monograph Capital in collaboration with GSK and has secured substantial funding from investors such as TPG, NEA, and Norwest. With a promising clinical stage asset and a robust discovery pipeline, Ouro Medicines is positioned to redefine treatment paradigms for immune-mediated diseases.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
25
Open positions
None listed
Dealroom signal
89.9/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Autoimmune, Immune System, Immunotherapy, Became $1B as Subsidiary, Biotech and Pharma, Cell Therapy, T Cell, DT and LS
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Mar 2026 $1.7B $1.7B Gilead Sciences ↗
SERIES AOther financing Jan 2025 $120M $480M UPMC Enterprises · TPG · NEA · Norwest Venture Partners ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Ouro Medicines website traffic

Latest recorded traffic for Ouro Medicines is 5.1K monthly website visits, up 82.1% over the last three months. Ouro Medicines's team grew 8.7% over the past year.

Latest monthly visits5.1K 3-month web change+82.1% 1-year team growth+8.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Ouro Medicines in the South San Francisco ecosystem

Live from Dealroom

The Ouro Medicines office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

Other known investors1 additional known investor

  • Gilead Sciences
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Ouro Medicines’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.